Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. has successfully completed a A$10.0 million capital raise, with the retail portion contributing A$6.9 million. This financial boost, strongly supported by investors including Tenmile and Ryder Capital, will propel the company’s growth and help expedite their U.S. objectives, including achieving CLIA waiver status for their FebriDx® point-of-care test in anticipation of the 2025 US flu season. Shares from the capital raise are expected to start trading on the ASX on 10 October 2024.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.